SPARC.NS
SPARC.NS
INE232I01014
SUN PHARMA ADV.RES.CO.LTD
Loading chart...

Company Profile

Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.

Related stocks

IOLCP.BO
IOLCP.BO • India
IOL CHEMICALS & PHARMACEUTICAL
200.85 INR
609.17M USD 1Y +100.2%
MOREPENLAB.NS
MOREPENLAB.NS • India
MOREPEN LAB. LTD
129.55 INR
733.49M USD 1Y +170.4%
AKUMS.NS
AKUMS.NS • India
AKUMS DRUGS AND PHARMA L
751.85 INR
1.19B USD 1Y +78.6%
FDC.BO
FDC.BO • India
FDC LTD.
330.1 INR
555.32M USD 1Y -27.9%
AARTIPHARM.NS
AARTIPHARM.NS • India
AARTI PHARMALABS LIMITED
855.5 INR
801.58M USD 1Y +2.5%
STAR.NS
STAR.NS • India
STRIDES PHARMA SCI LTD
1,085.3 INR
1.03B USD 1Y +37.4%
BLISSGVS.BO
BLISSGVS.BO • India
BLISS GVS PHARMA LTD.
644.55 INR
708.16M USD 1Y +341.4%
PGHL.BO
PGHL.BO • India
PROCTER & GAMBLE HEALTH LIMITE
5,215.55 INR
894.55M USD 1Y -17.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
49.2% p.a.
Max Drawdown (5Y)
-76.1%
Sharpe Ratio (5Y)
-0.22
Beta Factor
0.65
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (49.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -84.0% in the extended horizon.
ende